Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2015 Aug;35(8):4545-9.

Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports

Affiliations
  • PMID: 26168499
Case Reports

Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports

Toshio Inui et al. Anticancer Res. .

Abstract

Background: Gc protein-derived macrophage-activating factor (GcMAF) immunotherapy has been steadily advancing over the last two decades. Oral colostrum macrophage-activating factor (MAF) produced from bovine colostrum has shown high macrophage phagocytic activity. GcMAF-based immunotherapy has a wide application for use in treating many diseases via macrophage activation or for use as supportive therapy.

Results: Three case studies demonstrate that oral colostrum MAF can be used for serious infection and chronic fatigue syndrome (CFS) without adverse effects.

Conclusion: We demonstrate that colostrum MAF shows promising clinical results in patients with infectious diseases and for symptoms of fatigue, which is common in many chronic diseases.

Keywords: Immunotherapy; cancer; chronic fatigue syndrome (CFS); colostrum; macrophage-activating factor (MAF); myalgic encephalomyelitis (ME).

Similar articles

See all similar articles

Cited by 2 articles

Publication types

MeSH terms

Substances

LinkOut - more resources

Feedback